Advanced Filters
noise

Bethesda, Maryland Clinical Trials

A listing of Bethesda, Maryland clinical trials actively recruiting patient volunteers.

Found 1,597 clinical trials
J Julia C Finkel, MD

Therapeutic Endpoint in Pediatric IBD Conditions

The purpose of this clinical study is the development of physiologic endpoint of inflammation in pediatric patients diagnosed with inflammatory bowel disease (IBD), specifically subtypes Crohn's disease (CD) and ulcerative colitis (UC). The novel medical device evaluates the patient's sensory response to each of the three sensory nerve fiber types. …

6 - 21 years of age All Phase N/A
F For more information at the NIH Clinical Center contact NCI/Surgery Branch Recruitment Center

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Background A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells. Objective To see if anti-KRAS G12 V mTCR cells are safe …

18 - 72 years of age All Phase 1/2
B Bhruga Shah

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Pilot Prospective Randomized Unblinded Pragmatic Trial of Pulmonary Artery Hemodynamic Monitoring Following Hospitalization for Cardiogenic Shock

18 years of age All Phase N/A
K Kimberly Boucher, RN

Vosoritide for Short Stature in Turner Syndrome

Turner syndrome (TS) is characterized by a missing whole or part of the second sex chromosome in a phenotypic female, resulting in short stature due to haploinsufficiency of the short-stature homeobox-containing (SHOX) gene. Growth hormone (GH) is an approved therapy for this condition, although not associated with GH deficiency, and …

3 - 11 years of age Female Phase 2
N NCI Medical Oncology Referral Office

18F-Fluciclovine PET/CT in Multiple Myeloma

Background Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier. Objective To find out if the radiotracer 18F-fluciclovine (a …

18 - 120 years of age All Phase 2

A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening

To test the impact of a multilevel intervention on primary (provider-patient communication, intentions, and knowledge) and secondary (screening referrals and completion) outcomes.

50 - 80 years of age All Phase N/A
S Site Public Contact

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.

2 - 21 years of age All Phase 1/2
A A Munoz

Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial

This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.

18 - 84 years of age All Phase N/A
I Iris E Morris, PhD

The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction

This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment with teprotumumab infusion (Tepezza®). Patients recommended for treatment will be evaluated by an oculoplastic surgeon (Dr. Eva Chou) and endocrinologist …

18 years of age All Phase N/A
A Alyssa Savelli, MD

Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes

The goal of this study is to help identify the best antibiotic treatment for pregnant people when their water breaks prematurely (a condition abbreviated as PPROM). Current practice is to attempt to maintain the pregnancy until at least 34 weeks gestational age, when the risks of prematurity to the baby …

18 - 50 years of age Female Phase 3

Simplify language using AI